Data / Form D filings / Nexgenia Inc.
Nexgenia Inc.: Form D filings
Nexgenia Inc., a biotechnology company in Seattle, WA, filed 5 Form D notices with the SEC between 2014 and 2018. The latest, on May 15, 2018, reports $119,099 sold of a $250,000 offering to 14 investors.
Find out what Nexgenia Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 454 NORTH 34TH ST., SUITE LL, Seattle, WA, 98103
- Phone
- (206) 290-8902
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1623317
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 15, 2018 | New notice | $250,000 | $119,099 | $130,901 | 14 | May 8, 2018 | sec.gov |
| Apr 5, 2017 | New notice | $1,900 | $0 | $1,900 | 1 | Mar 23, 2017 | sec.gov |
| Aug 19, 2016 | New notice | $2,000,000 | $1,859,887 | $140,113 | 15 | Aug 5, 2016 | sec.gov |
| Jun 29, 2015 | New notice | $3,547,583 | $1,617,582 | $1,930,001 | 9 | Jun 17, 2015 | sec.gov |
| Oct 28, 2014 | New notice | $1,000,000 | $500,000 | $500,000 | 2 | Oct 14, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Steven Gillis | Director | |
| Stewart Parker | Director | |
| Ron Myers | Executive Officer, Director | |
| David Urdal | Director | |
| Martin Simonetti | Director | |
| Charles P. Waite | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of May 14, 2018 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Nexgenia Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.